ERBB2 and breast cancer: Ten to fifteen percent of breast cancers in Western women are triple-negative breast cancers (TNBCs), which do not express the estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2) and have a poor overall prognosis and high recurrence risk [2].